Cargando…
Discovery of Hepatitis C Virus: 2020 Nobel Prize in Medicine
Hepatitis C virus (HCV) accounts for hepatitis, liver cirrhosis, hepatocellular carcinoma, and liver transplantation. This virus is a single-stranded RNA virus that belongs to the Flaviviridae family. According to the WHO, about 71 million people have chronic HCV infections around the globe in 2020,...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Jaypee Brothers Medical Publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801885/ https://www.ncbi.nlm.nih.gov/pubmed/33511075 http://dx.doi.org/10.5005/jp-journals-10018-1326 |
_version_ | 1783635666523914240 |
---|---|
author | Laugi, Hemshankar |
author_facet | Laugi, Hemshankar |
author_sort | Laugi, Hemshankar |
collection | PubMed |
description | Hepatitis C virus (HCV) accounts for hepatitis, liver cirrhosis, hepatocellular carcinoma, and liver transplantation. This virus is a single-stranded RNA virus that belongs to the Flaviviridae family. According to the WHO, about 71 million people have chronic HCV infections around the globe in 2020, and hence, it is a plague of humankind. The credit of discovery of HCV goes to Michael Houghton, Harvey Alter, and Charles Rice for which they are awarded 2020 Nobel Prize in Medicine. Their contribution has given better hope to mankind to cure HCV for the first time in the history. With the use of pegylated interferon and ribavirin jointly, higher SVR has been found comparatively, even in patients with chronic liver diseases. However, due to excessive pain tolerated by patients, interferon (IFN)-based therapy is rapidly being replaced with IFN-free DAA regimens. With the onset of resistance to DAA drugs, CRISPR-Cas system can be used to modify the viral genome to impair their ability to develop resistance. How to cite this article: Laugi H. Discovery of Hepatitis C Virus: 2020 Nobel Prize in Medicine. Euroasian J Hepato-Gastroenterol 2020;10(2): 105–108. |
format | Online Article Text |
id | pubmed-7801885 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Jaypee Brothers Medical Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-78018852021-01-27 Discovery of Hepatitis C Virus: 2020 Nobel Prize in Medicine Laugi, Hemshankar Euroasian J Hepatogastroenterol Short Communication Hepatitis C virus (HCV) accounts for hepatitis, liver cirrhosis, hepatocellular carcinoma, and liver transplantation. This virus is a single-stranded RNA virus that belongs to the Flaviviridae family. According to the WHO, about 71 million people have chronic HCV infections around the globe in 2020, and hence, it is a plague of humankind. The credit of discovery of HCV goes to Michael Houghton, Harvey Alter, and Charles Rice for which they are awarded 2020 Nobel Prize in Medicine. Their contribution has given better hope to mankind to cure HCV for the first time in the history. With the use of pegylated interferon and ribavirin jointly, higher SVR has been found comparatively, even in patients with chronic liver diseases. However, due to excessive pain tolerated by patients, interferon (IFN)-based therapy is rapidly being replaced with IFN-free DAA regimens. With the onset of resistance to DAA drugs, CRISPR-Cas system can be used to modify the viral genome to impair their ability to develop resistance. How to cite this article: Laugi H. Discovery of Hepatitis C Virus: 2020 Nobel Prize in Medicine. Euroasian J Hepato-Gastroenterol 2020;10(2): 105–108. Jaypee Brothers Medical Publishers 2020 /pmc/articles/PMC7801885/ /pubmed/33511075 http://dx.doi.org/10.5005/jp-journals-10018-1326 Text en Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd. © The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Short Communication Laugi, Hemshankar Discovery of Hepatitis C Virus: 2020 Nobel Prize in Medicine |
title | Discovery of Hepatitis C Virus: 2020 Nobel Prize in Medicine |
title_full | Discovery of Hepatitis C Virus: 2020 Nobel Prize in Medicine |
title_fullStr | Discovery of Hepatitis C Virus: 2020 Nobel Prize in Medicine |
title_full_unstemmed | Discovery of Hepatitis C Virus: 2020 Nobel Prize in Medicine |
title_short | Discovery of Hepatitis C Virus: 2020 Nobel Prize in Medicine |
title_sort | discovery of hepatitis c virus: 2020 nobel prize in medicine |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801885/ https://www.ncbi.nlm.nih.gov/pubmed/33511075 http://dx.doi.org/10.5005/jp-journals-10018-1326 |
work_keys_str_mv | AT laugihemshankar discoveryofhepatitiscvirus2020nobelprizeinmedicine |